The human ortholog of granulocyte macrophage colony-stimulating factor and interleukin-2 fusion protein induces potent ex vivo natural killer cell activation and maturation

Cancer Research

Volumn 69, Issue 23, 2009, Pages 9020-9028

  Penafuerte, Claudia ^a   Bautista Lopez, Norma ^c   Mohamed Rachid, Boulassel ^b   Routy, Jean Pierre ^b   Galipeau, Jacques ^a,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD69 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; HUMAN ORTHOLOG OF GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR INTERLEUKIN 2 FUSION PROTEIN; HYBRID PROTEIN; IMMUNOSTIMULATING AGENT; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR BETA; JANUS KINASE 1; JANUS KINASE 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; NATURAL KILLER CELL RECEPTOR; RANTES; RECOMBINANT INTERLEUKIN 2; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CELL MATURATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; ENZYME ACTIVATION; EX VIVO STUDY; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LYMPHOCYTE ACTIVATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TUMOR CELL; UPREGULATION;

AMINO ACID SEQUENCE; CELL LINE; DNA, COMPLEMENTARY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-2; JANUS KINASES; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MOLECULAR SEQUENCE DATA; RECEPTORS, IMMUNOLOGIC; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 71549128406     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-2322     Document Type: Article

References (35)

1. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989;47:187-376.
2. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097-2100 (Pubitemid 34229476)
3. Bottino C, Moretta L, Pende D, Vitale M, Moretta A. Learning how to discriminate between friends and enemies, a lesson from natural killer cells. Mol Immunol 2004;41:569-575 (Pubitemid 38824614)
4. Penafuerte C, Galipeau J. TGF β secreted by B16 melanoma antagonizes cancer gene immunotherapy bystander effect. Cancer Immunol Immunother 2008;57:1197-1206
5. Stagg J, Wu JH, Bouganim N, Galipeau J. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy. Cancer Res 2004;64:8795-8799 (Pubitemid 39665478)
6. Galipeau J, Li H, Paquin A, Sicilia F, Karpati G, Nalbantoglu J. Vesicular stomatitis virus G pseudo-typed retrovector mediates effective in vivo suicide gene delivery in experimental brain cancer. Cancer Res 1999;59:2384-2394 (Pubitemid 29242287)
7. Zheng X, Wang Y, Wei H, Ling B, Sun R, Tian Z. Bcl-xL is associated with the anti-apoptotic effect of IL-15 on the survival of CD56(dim) natural killer cells. Mol Immunol 2008;45:2559-2569
8. Marks-Konczalik J, Dubois S, Losi JM, et al. IL-2- induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci U S A 2000;97:11445-11450 (Pubitemid 30780914)
9. Faisal M, Cumberland W, Champlin R, Fahey JL. Effect of recombinant human granulocyte-macrophage colony-stimulating factor administration on the lymphocyte subsets of patients with refractory aplastic anemia. Blood 1990;76:1580-1585 (Pubitemid 20364022)
10. Giron-Michel J, Fogli M, Gaggero A, et al. Detection of a functional hybrid receptor γc/GM-CSFRβ in human hematopoietic CD34+ cells. J Exp Med 2003;197:763-775 (Pubitemid 36350871)
11. Yu TK, Caudell EG, Smid C, Grimm EA. IL-2 activation of NK cells: involvement of MKK1/2/ERK but not p38 kinase pathway. J Immunol 2000;164:6244-6251 (Pubitemid 30408804)
12. Martinez-Moczygemba M, Huston DP. Biology of common β receptor-signaling cytokines: IL-3, IL-5, and GM-CSF. J Allergy Clin Immunol 2003;112:653-665 (Pubitemid 37260379)
13. Koulova L, Novik Y, Caliendo G, Wiernik P, Dutcher J. A phase 2 study of moderate dose interleukin-2 and granulocyte-macrophage colony-stimulating factor in patients with metastatic or unresectable renal cell carcinoma. J Immunother 2005;28:576-581 (Pubitemid 41533091)
14. Schiller JH, Hank JA, Khorsand M, et al. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study. Clin Cancer Res 1996;2:319-330 (Pubitemid 26075639)
15. Pessino A, Sivori S, Bottino C, et al. Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J Exp Med 1998;188:953-960 (Pubitemid 28433421)
16. Pende D, Parolini S, Pessino A, et al. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 1999;190:1505-1516
17. Vitale M, Bottino C, Sivori S, et al. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med 1998;187:2065-2072 (Pubitemid 28285576)
18. Sivori S, Pende D, Bottino C, et al. NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. Eur J Immunol 1999;29:1656-1666 (Pubitemid 29224471)
19. Tahara-Hanaoka S, Shibuya K, Kai H, et al. Tumor rejection by the poliovirus receptor family ligands of the DNAM-1 (CD226) receptor. Blood 2006;107:1491-1496 (Pubitemid 43242386)
20. Masucci MG, Bejarano MT, Masucci G, Klein E. Large granular lymphocytes inhibit the in vitro growth of autologous Epstein-Barr virus-infected B cells. Cell Immunol 1983;76:311-321
21. Jiang YZ, Couriel D, Mavroudis DA, et al. Interaction of natural killer cells with MHC class II: reversal of HLA-DR1-mediated protection of K562 transfectant from natural killer cell-mediated cytolysis by brefeldin-A. Immunology 1996;87:481-486 (Pubitemid 26101270)
22. Okamoto M, Inaba T, Yamada N, et al. Expression and role of MHC class I-related chain in myeloma cells. Cytotherapy 2006;8:509-516 (Pubitemid 44597003)
23. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-γ. Annu Rev Immunol 1997;15:749-795
24. Maghazachi AA. Differential effects of various cytokines on the generation of rat LAK cells from their purified precursors. Immunology 1990;70:465-472
25. Samson SI, Memet S, Vosshenrich CA, et al. Combined deficiency in IκBα and IκBε reveals a critical window of NF-κB activity in natural killer cell differentiation. Blood 2004;103:4573-4580 (Pubitemid 38745985)
26. Robbins SH, Tessmer MS, Mikayama T, Brossay L. Expansion and contraction of the NK cell compartment in response to murine cytomegalovirus infection. J Immunol 2004;173:259-266 (Pubitemid 38797350)
27. Sadhu C, Harris EA, Staunton DE. Enhancement of Natural Killer cell cytotoxicity by a CD18 integrin-activating antibody. Biochem Biophys Res Commun 2007;358:938-941 (Pubitemid 46802480)
28. Bordignon C, Carlo-Stella C, Colombo MP, et al. Cell therapy: achievements and perspectives. Haematologica 1999;84:1110-1149
29. Fehniger TA, Cooper MA, Caligiuri MA. Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev 2002;13:169-183
30. Rodella L, Zamai L, Rezzani R, et al. Interleukin 2 and interleukin 15 differentially predispose natural killer cells to apoptosis mediated by endothelial and tumour cells. Br J Haematol 2001;115:442-450 (Pubitemid 34203515)
31. Capobianco A, Manfredi AA, Monno A, Rovere-Querini P, Rugarli C. Melanoma and lymphoma rejection associated with eosinophil infiltration upon intratumoral injection of dendritic and NK/LAK cells. J Immunother 2008;31:458-465
32. Velardi A, Ruggeri L, Moretta A, Moretta L. NK cells: a lesson from mismatched hematopoietic transplantation. Trends Immunol 2002;23:438-444 (Pubitemid 35015187)
33. Aversa F, Terenzi A, Tabilio A, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005;23:3447-3454 (Pubitemid 46249699)
34. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999;285:412-415 (Pubitemid 29343964)
35. Vitale C, Chiossone L, Morreale G, et al. Analysis of the activating receptors and cytolytic function of human natural killer cells undergoing in vivo differentiation after allogeneic bone marrow transplantation. Eur J Immunol 2004;34:455-460 (Pubitemid 39255956)